Zenas BioPharma (NASDAQ:ZBIO) Downgraded to “Strong Sell” Rating by Wall Street Zen

Zenas BioPharma (NASDAQ:ZBIO) was downgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “strong sell” rating in a research report issued to clients and investors on Saturday.

ZBIO has been the topic of a number of other reports. Wedbush reaffirmed an “outperform” rating and set a $45.00 price objective on shares of Zenas BioPharma in a research note on Monday, December 22nd. Guggenheim lifted their price objective on Zenas BioPharma from $45.00 to $55.00 and gave the company a “buy” rating in a research report on Monday. Citigroup reduced their target price on shares of Zenas BioPharma from $43.00 to $41.00 and set a “buy” rating on the stock in a research report on Tuesday. Zacks Research cut Zenas BioPharma from a “hold” rating to a “strong sell” rating in a research note on Tuesday. Finally, Morgan Stanley raised their price target on shares of Zenas BioPharma from $19.00 to $21.00 and gave the company an “equal weight” rating in a research report on Tuesday. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Zenas BioPharma has an average rating of “Hold” and a consensus target price of $44.14.

Zenas BioPharma Stock Performance

ZBIO opened at $22.30 on Friday. Zenas BioPharma has a 12-month low of $6.11 and a 12-month high of $44.60. The stock has a market cap of $1.28 billion, a price-to-earnings ratio of -2.86 and a beta of -1.94. The business has a 50 day moving average of $23.17 and a 200-day moving average of $27.16. The company has a quick ratio of 5.66, a current ratio of 5.61 and a debt-to-equity ratio of 0.32.

Zenas BioPharma (NASDAQ:ZBIO) last issued its quarterly earnings results on Monday, March 16th. The company reported ($4.54) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.22) by ($3.32).

Insiders Place Their Bets

In other Zenas BioPharma news, Director Hongbo Lu purchased 25,985 shares of the company’s stock in a transaction dated Wednesday, February 11th. The shares were acquired at an average price of $22.50 per share, for a total transaction of $584,662.50. Following the purchase, the director directly owned 347,968 shares of the company’s stock, valued at $7,829,280. The trade was a 8.07% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Patricia L. Allen acquired 15,700 shares of Zenas BioPharma stock in a transaction dated Thursday, February 12th. The stock was bought at an average price of $24.85 per share, with a total value of $390,145.00. Following the completion of the purchase, the director directly owned 15,700 shares in the company, valued at $390,145. This represents a ∞ increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last three months, insiders have bought 202,845 shares of company stock valued at $3,747,185. Insiders own 16.50% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ZBIO. Quarry LP grew its stake in shares of Zenas BioPharma by 34.5% in the 3rd quarter. Quarry LP now owns 1,134 shares of the company’s stock worth $25,000 after buying an additional 291 shares in the last quarter. Russell Investments Group Ltd. purchased a new stake in shares of Zenas BioPharma during the 3rd quarter valued at about $30,000. GF Fund Management CO. LTD. bought a new position in shares of Zenas BioPharma in the 4th quarter valued at about $38,000. BNP Paribas Financial Markets lifted its holdings in shares of Zenas BioPharma by 120.0% in the 3rd quarter. BNP Paribas Financial Markets now owns 3,146 shares of the company’s stock valued at $70,000 after acquiring an additional 1,716 shares during the last quarter. Finally, CWM LLC grew its position in Zenas BioPharma by 48.3% in the fourth quarter. CWM LLC now owns 2,178 shares of the company’s stock worth $79,000 after acquiring an additional 709 shares in the last quarter.

Key Stories Impacting Zenas BioPharma

Here are the key news stories impacting Zenas BioPharma this week:

• Positive Sentiment: HC Wainwright reiterated a “Buy” rating and a $44 price target for Zenas BioPharma, a reaffirmation that can support longer-term investor interest despite other negative headlines. HC Wainwright Reiterates Buy Rating for Zenas BioPharma (NASDAQ:ZBIO)
• Neutral Sentiment: HC Wainwright published detailed forward EPS models (FY2026–FY2030) outlining updated multi‑year loss assumptions; these give investors a clearer roadmap for expected cash burn and timeline to potential improvement but are forecasts rather than company actions. ZBIO analyst estimates (MarketBeat)
• Negative Sentiment: Zacks downgraded Zenas BioPharma from “hold” to “strong sell,” a headline that can accelerate outflows from more conservative holders. Zacks.com
• Negative Sentiment: HC Wainwright cut near‑term EPS estimates across multiple quarters and fiscal years (Q1–Q4 2026 and FY2026–FY2029), materially widening projected losses for 2026–2028 versus prior forecasts; earnings downgrades typically pressure shares as they reduce near‑term visibility into profitability. ZBIO analyst estimates (MarketBeat)
• Negative Sentiment: Recent posted quarterly results showed a large EPS miss, reinforcing analyst downgrades and increasing near‑term uncertainty around execution and cash needs. ZBIO company/earnings information (MarketBeat)

Zenas BioPharma Company Profile

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.